Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Harbor Capital Advisors Inc. trimmed its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,500 shares of the company's stock after selling 35,407 shares during the period. Harbor Capital Advisors Inc. owned about 0.42% of Castle Biosciences worth $3,158,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Castle Biosciences by 165.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock worth $1,980,000 after purchasing an additional 43,241 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock worth $43,879,000 after buying an additional 40,377 shares during the last quarter. Franklin Resources Inc. increased its holdings in Castle Biosciences by 87.3% in the third quarter. Franklin Resources Inc. now owns 69,382 shares of the company's stock worth $1,979,000 after buying an additional 32,344 shares during the last quarter. Barclays PLC raised its position in Castle Biosciences by 310.7% during the third quarter. Barclays PLC now owns 52,301 shares of the company's stock valued at $1,491,000 after acquiring an additional 39,567 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Castle Biosciences by 1.1% in the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company's stock valued at $17,820,000 after acquiring an additional 7,004 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Castle Biosciences Stock Performance

CSTL traded down $2.47 during midday trading on Friday, reaching $30.25. The company's stock had a trading volume of 1,196,393 shares, compared to its average volume of 478,132. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $29.81 and a 200 day simple moving average of $27.91. The stock has a market cap of $847.21 million, a P/E ratio of 151.26 and a beta of 0.92. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same quarter last year, the company posted ($0.26) earnings per share. Research analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Insider Transactions at Castle Biosciences

In other news, insider Tobin W. Juvenal sold 3,507 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the sale, the insider now directly owns 54,178 shares in the company, valued at approximately $1,926,569.68. The trade was a 6.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.14, for a total value of $229,244.38. Following the completion of the transaction, the director now owns 1,425 shares of the company's stock, valued at $41,524.50. The trade was a 84.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,292 shares of company stock worth $1,099,755. 7.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CSTL. Robert W. Baird increased their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. KeyCorp boosted their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Stephens reissued an "overweight" rating and set a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Canaccord Genuity Group boosted their target price on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. Finally, Lake Street Capital lifted their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $40.29.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.